Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML ‐ IPC ‐ AURAML consortium
British Journal of Haematology · 2026-11 · 209 (5) · 2160-2167
DOI: 10.1111/bjh.70815 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift British Journal of Haematology, online erschienen am 04.09.2026. Verfasst von Pierre-Yves Dumas und 22 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Bordeaux, INSERM, BRIC, U1312, CHU Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Cytarabine, Azacitidine, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Complete remission (CR) rates for patients with acute myeloid leukaemia (AML) treated with intensive chemotherapy (IC) have increasingly improved. Yet, relapse remains a concern with a dismal prognosis. In this report, results are presented of a retrospective analysis comparing salvage therapy based on intermediate (I) or high (H)‐dose cytarabine (DAC) ( n = 203) and venetoclax‐azacitidine (VEN‐AZA) ( n = 114) for patients with AML in first relapse. Patients (median age 60 years, interquartile range [IQR] 48–67) had reached CR1 after a standard 7 + 3 ( n = 305) or CPX351 schedule ( n = 12). I/HDAC‐based and VEN‐AZA salvage, respectively, resulted in CR2 in 66.0% and 66.7% of the patients ( p = 0.96). Allogeneic haematopoietic stem cell transplantation (allo‐HSCT) was performed for 115 patients in CR2 and 18 in failure. Relapse‐free survival was 13.2 (IQR 7.0‐not reached [NR]) and 13.7 (IQR 7.8‐NR) months while overall survival (OS) was 14.5 (IQR 6.2‐NR) and 12.3 months (IQR 4.8‐NR; p = 0.41) for patients who received I/HDAC‐based salvage and VEN‐AZA respectively. In multivariable analysis, relapsing patients ≥60 years with low/intermediate‐risk cytogenetics and VEN‐AZA had a better OS ( p = 0.002), while I/HDAC was more efficient for those with poor risk cytogenetics and < 60‐year‐old ( p = 0.002). VEN‐AZA salvage therapy thus appears promising compared with conventional I/HDAC‐based IC; this question warrants evaluation in randomized studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ. Bordeaux, INSERM, BRIC, U1312, CHU Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France.
- Université de Toulouse, CHU de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Service d'Hématologie, Toulouse, France.
- Department of Clinical Epidemiology and Public Health, CERPOP, INSERM-University of Toulouse III, Toulouse University Hospital (CHU), Toulouse, France.
- Department of Hematology, CH de Valence, Valence, France.
- Department of Hematology, CHU Lyon Sud, Lyon, France.
- Aix-Marseille University, INSERM U1068, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France.
ORCID-Profile: Pierre-Yves Dumas, Maël Heiblig, Thibaut Leguay, Estelle Borgne, Laetitia Largeaud, Morgane Sighieri, Emilie Klein, Emmanuelle Tavernier, Martin Carré, Gaspar Aspas Requena, Anne Banos, Arnaud Pigneux, Christian Récher, Sylvain Garciaz
Zitieren
APA
Dumas, P. Y., Bertoli, S., Bérard, E., Santana, C., Heiblig, M., Leguay, T., Tavitian, S., Borgne, E., de Grande, A. C., Sarry, A., Acheaibi, Z., Largeaud, L., Sighieri, M., Klein, E., Tavernier, E., Hospital, M. A., Carré, M., Requena, G. A., Banos, A., …, & Garciaz, S. (2026). Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML ‐ IPC ‐ AURAML consortium. British Journal of Haematology, 209(5), 2160-2167. https://doi.org/10.1111/bjh.70815
Vancouver
Dumas PY, Bertoli S, Bérard E, Santana C, Heiblig M, Leguay T, et al. Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML ‐ IPC ‐ AURAML consortium. British Journal of Haematology. 2026;209(5):2160-2167. doi:10.1111/bjh.70815
BibTeX
@article{Dumas2026,
author = {Dumas, Pierre-Yves and Bertoli, Sarah and Bérard, Emilie and Santana, Clémence and Heiblig, Maël and Leguay, Thibaut and Tavitian, Suzanne and Borgne, Estelle and de Grande, Anne-Charlotte and Sarry, Audrey and Acheaibi, Ziyad and Largeaud, Laetitia and Sighieri, Morgane and Klein, Emilie and Tavernier, Emmanuelle and Hospital, Marie-Anne and Carré, Martin and Requena, Gaspar Aspas and Banos, Anne and Vey, Norbert and Pigneux, Arnaud and Récher, Christian and Garciaz, Sylvain},
title = {Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML ‐ IPC ‐ AURAML consortium},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {5},
pages = {2160--2167},
doi = {10.1111/bjh.70815}
}
EUVIMED